|
LA JOLLA PHARMACEUTICAL TO PRESENT AT PACIFIC GROWTH EQUITIES
LIFE SCIENCES CONFERENCE
SAN DIEGO, June 2, 2005 – La Jolla Pharmaceutical Company
(Nasdaq: LJPC) today announced that Steven B. Engle, Chairman
and CEO of La Jolla Pharmaceutical, will present on Wednesday,
June 8th at 8:00 a.m. at the Pacific Growth Equities Life Sciences
Growth Conference. The conference will take place at the Mark
Hopkins Inter-Continental Hotel in San Francisco. An audio webcast
of the presentation will be available through the Company’s
Web site: http://www.ljpc.com.
La Jolla Pharmaceutical Company is a biotechnology company
developing therapeutics for antibody-mediated autoimmune diseases
and inflammation afflicting several million people in the United
States and Europe. The Company is developing Riquent® for
the treatment of lupus kidney disease, a leading cause of sickness
and death in patients with lupus. The Company is also developing
small molecules to treat various other autoimmune and inflammatory
conditions. The Company's common stock is traded on The Nasdaq
Stock Market under the symbol LJPC. For more information about
the Company, visit its Web site: http://www.ljpc.com.
The forward-looking statements in this press release involve significant
risks and uncertainties, and a number of factors, both foreseen
and unforeseen, could cause actual results to differ materially
from our current expectations. Forward-looking statements include
those that express a plan, belief, expectation, estimation, anticipation,
intent, contingency, future development or similar expression.
Although we are seeking collaborative agreements to support the
development of Riquent and our small molecule inflammation program,
we cannot guarantee that we will be successful in establishing
any such collaborative agreements or that the terms of any potential
agreements will result in the payment of significant funds to
us. The analyses of clinical results of Riquent, previously known
as LJP 394, our drug candidate for the treatment of systemic lupus
erythematosus ("lupus"), and any other drug candidate
that we may develop, including the results of any trials that
are ongoing or that we may initiate in the
future, could result in a finding that these drug candidates are
not effective in large patient populations, do not provide a meaningful
clinical benefit, or may reveal a potential safety issue requiring
us to develop new candidates. The analysis of the data from our
Phase 3 trial of Riquent showed that the trial did not reach statistical
significance with respect to its primary endpoint, time to renal
flare, or with respect to the secondary endpoint, time to treatment
with high-dose corticosteroids or cyclophosphamide. The results
from our clinical trials of Riquent, including the results of
any trials that are ongoing or that we may initiate in the future,
may not ultimately be sufficient to obtain regulatory clearance
to market Riquent either in the United States or Europe, and we
may be required to conduct additional clinical studies to demonstrate
the safety and efficacy of Riquent in order to obtain marketing
approval. There can be no assurance, however, that we will have
the necessary resources to complete any current or future trials
or that any such trials will sufficiently demonstrate the safety
and efficacy of Riquent. Our blood test to measure the binding
affinity for Riquent is experimental, has not been validated by
independent laboratories and will likely be reviewed as part of
the Riquent approval process. Our other potential drug candidates
are at earlier stages of development and involve comparable risks.
Analysis of our clinical trials could have negative or inconclusive
results. Any positive results observed to date may not be indicative
of future results. In any event, regulatory authorities may require
clinical trials in addition to our current clinical trial, or
may not approve our drugs. Our ability to develop and sell our
products in the future may be adversely affected by the intellectual
property rights of third parties. Additional risk factors include
the uncertainty and timing of: our clear need for additional financing
or a collaborative agreement; obtaining required regulatory approvals,
including delays associated with any approvals that we may obtain;
our ability to pass all necessary FDA inspections; the increase
in capacity of our manufacturing capabilities for possible commercialization;
successfully marketing and selling our products; our lack of manufacturing,
marketing and sales experience; our ability to make use of the
orphan drug designation for Riquent; generating future revenue
from product sales or other sources such as collaborative relationships;
future profitability; and our dependence on patents and other
proprietary rights. Readers are cautioned to not place undue reliance
upon forward-looking statements, which speak only as of the date
hereof, and we undertake no obligation to update forward-looking
statements to reflect events or circumstances occurring after
the date hereof. Interested parties are urged to review the risks
described in our Annual Report on Form 10-K for the year ended
December 31, 2004, and in other reports and registration statements
that we file with the Securities and Exchange Commission from
time to time
Terms
of Use & Privacy Policy
Copyright © 2008, La Jolla Pharmaceutical Company
|